BHBausch Health BHC · NYSE
$6.47 +0.23% (+$0.02)
- Market cap
- $2.41B
- Enterprise value
- $21.4B
- P/E
- -
- Forward P/E
- 1.4x
- PEG
- -
- P/S
- 0.2x
- P/FCF
- 1.7x
- EV/EBITDA
- 10.4x
- ROIC
- 19.5%
- Gross margin
- 71.8%
- Net margin
- -10.1%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- 9.3x
- Beta
- 0.37
- Free float
- 88.6%
About the company
Bausch Health Companies Inc. is a Canadian pharmaceutical company focused on the development and manufacturing of medicines and healthcare products. Originally founded in 1959 as Valeant Pharmaceuticals, the company rebranded as Bausch Health in 2018, shifting its focus to products in ophthalmology, dermatology, dental care, and cardiovascular medicine. Bausch Health specializes in prescription drugs, over-the-counter products, and innovative medical devices, and is known for its strong portfolio in ophthalmology and medical technologies.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Thomas J. Appio
Employees
20,300
Headquarters
Laval
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number